Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Next Previous
Drug Profile

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Alternative Names: BGB 324; BGB-3234; R-428

Latest Information Update: 08 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; Oslo University Hospital; University of Leicester; University of Texas Health Science Center at San Antonio; University of Texas Southwestern Medical Center
  • Class Antifibrotics; Antineoplastics; Antivirals; Benzocycloheptenes; Cycloheptanes; Hepatoprotectants; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Malignant-mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer; Triple negative breast cancer
  • Phase I/II Adenocarcinoma; Glioblastoma; Pancreatic cancer
  • Preclinical Adult respiratory distress syndrome; Influenza virus infections; Respiratory syncytial virus infections; Rhinovirus infections
  • No development reported Chronic myeloid leukaemia; Ebola virus infections; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Solid tumours; Zika virus infection

Most Recent Events

  • 08 Sep 2025 Phase-II clinical trials in COVID-2019 infections in Belgium, Czech Republic, France, Greece, Ireland, Italy, Luxembourg, Norway, Slovakia, Spain (PO) (CTIS2022-500363-12-00)
  • 09 May 2025 BerGenBio ASA terminates a phase I/II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in United Kingdom, Italy, Greece, France, Poland, USA, Hungary, Spain (PO) due to lack of efficacy (NCT05469178)
  • 25 Apr 2025 Pharmacodynamics data from preclinical studies in Non small cell cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top